2023
DOI: 10.1016/j.obpill.2023.100080
|View full text |Cite
|
Sign up to set email alerts
|

Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
8
0
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 23 publications
(10 citation statements)
references
References 18 publications
1
8
0
1
Order By: Relevance
“…This means that food intake was reduced in SEMA treated INT animals compared to controls even on non-binge days. Our findings further the literature by demonstrating a reduction in binge episode size in a rodent model in a controlled setting, as current studies have focused on selfreport of small human cohorts without monitoring food intake directly [22,23].…”
Section: Discussionsupporting
confidence: 83%
See 1 more Smart Citation
“…This means that food intake was reduced in SEMA treated INT animals compared to controls even on non-binge days. Our findings further the literature by demonstrating a reduction in binge episode size in a rodent model in a controlled setting, as current studies have focused on selfreport of small human cohorts without monitoring food intake directly [22,23].…”
Section: Discussionsupporting
confidence: 83%
“…For example, SEMA was found to decrease alcoholinduced locomotor activity and the release of dopamine in the nucleus accumbens (NAc) after alcohol consumption in rodents, suggesting alterations in reward and motivation processes [16]. SEMA was also shown to be more effective than other obesity medications at reducing reported binge eating scores in a small cohort study in humans [17]. While promising, these studies warrant greater investigation into the physiological mechanisms underlying SEMA's effects.…”
Section: Glucagon-like Peptide-1 and Binge Eatingmentioning
confidence: 99%
“…23 Participants receiving liraglutide showed a significant improvement in binge eating, accompanied by a reduction in body mass index, systolic blood pressure, glucose, and cholesterol plasma concentrations. 23 One retrospective study on the effects of semaglutide on BED reported similar results in the semaglutide group compared with study participants who received lisdexamfetamine or topiramate, 24 which are recommended treatments for BED. 25 However, only a single pilot RCT has been published so far that tested the GLP-1 receptor agonist liraglutide in people with BED.…”
Section: Possible Psychiatric Indicationsmentioning
confidence: 92%
“…We are acutely aware of the societal stigma surrounding obesity 34 and strongly oppose any form of weight-or body-related discrimination. Acknowledging obesity's potential health repercussions and impact on quality of life, we recognize that GLP-1 agonists may significantly enhance health outcomes when used judiciously, even in individuals with certain forms of eating disorders 35 or addiction. 36,37 We advocate for a multidisciplinary approach to obesity treatment, involving close collaboration among various healthcare specialists (psychiatrists, psychologists, psychotherapists, dieticians and other healthcare professionals) to ensure tailored and comprehensive care.…”
Section: Acknowledgmentsmentioning
confidence: 99%